Latrepirdine ( DrugBank: Latrepirdine )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 8 | ハンチントン病 | 10 |
8. ハンチントン病
臨床試験数 : 229 / 薬物数 : 193 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-018123-32-SE (EUCTR) | 30/09/2010 | 10/06/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| 2 | EUCTR2009-018123-32-NL (EUCTR) | 23/08/2010 | 14/04/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| 3 | EUCTR2009-018123-32-IT (EUCTR) | 28/07/2010 | 15/07/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-Plus | Huntington`s Corea MedDRA version: 9.1;Level: LLT;Classification code 10020469 | Product Name: Dimebon INN or Proposed INN: Dimebon dihydrochloride Product Name: Dimebon INN or Proposed INN: Dimebon dihydrochloride | MEDIVATION, INC. | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| 4 | EUCTR2009-018123-32-DE (EUCTR) | 07/06/2010 | 02/03/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden | |||
| 5 | EUCTR2009-018123-32-GB (EUCTR) | 14/05/2010 | 18/03/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | |||
| 6 | EUCTR2009-018123-32-DK (EUCTR) | 23/04/2010 | 16/03/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| 7 | NCT01085266 (ClinicalTrials.gov) | February 2010 | 10/3/2010 | An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | Huntington Disease | Drug: Dimebon (latrepirdine) | Medivation, Inc. | Pfizer;Pfizer | Terminated | 30 Years | N/A | Both | 362 | Phase 3 | NULL |
| 8 | NCT00975481 (ClinicalTrials.gov) | October 2009 | 10/9/2009 | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | Alzheimer's Disease;Huntington's Disease | Drug: dimebon;Drug: placebo;Drug: alprazolam | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | All | 36 | Phase 1 | Canada |
| 9 | NCT00990613 (ClinicalTrials.gov) | October 2009 | 6/10/2009 | A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin | A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon IR;Drug: Dimebon Transdermal | Pfizer | Medivation, Inc. | Completed | 50 Years | 85 Years | Both | 19 | Phase 1 | United States |
| 10 | NCT00988624 (ClinicalTrials.gov) | October 2009 | 1/10/2009 | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | Alzheimer's Disease;Huntington Disease | Drug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4 | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 20 | Phase 1 | United States |